Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients.
A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.
Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated.
The use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in kidney cancer could offer important new treatment options. Questions remain, though, on the timing and sequence of therapy.
Expression of MET as measured by immunohistochemistry was not associated with any difference in the performance of cabozantinib as compared with everolimus in patients with advanced renal cell carcinoma.